Black men have lower preference for investigation of prostate cancer
the ONA take:
According to a recent study published in the British Journal of General Practice, researchers from University of Exeter Medical School in Exeter, United Kingdom, have found that black men are less willing to be investigated for prostate cancer, thereby increasing the likelihood of being diagnosed as emergencies and having a higher mortality rate compared with white men.
For the study, researchers identified over 500 men attending general practices in Bristol, United Kingdom, and presented them with realistic hypothetical scenarios in which the participants was given a description of a prostate cancer symptom and the estimated risk of prostate cancer.
Results showed that black men were less likely to prefer investigation of the symptom despite the risk given in the scenario. Researchers found that when participants were presented with scenarios associated with the lowest risk level, only 44% of black males opted for investigation versus 91% of white males.
Among both groups, the most common reason for choosing not to investigate the symptom was low risk, but significantly more black participants reported that they did not want to know if they had cancer.
The findings suggest that health care professionals should proactively discuss the subject of cancer with their patients and education targeted at the black community may help reduce fear of cancer investigation.
Black men are less willing to be investigated for prostate cancer, thereby increasing the likelihood of being diagnosed.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|